David Webb

Q: What Schools Are Affiliated With David Webb

David Webb is affiliated with the following schools: University of Cambridge, Robert Gordon University, University of California, Berkeley, University of Strathclyde, University College London, St George's, University of London, Royal Postgraduate Medical School, University of Edinburgh, Stanford University, University of California, San Francisco

David Webb 's AcademicInfluence.com Rankings

David Webb

Medical

#666

World Rank

#889

Historical Rank

Pharmacology

#72

World Rank

#95

Historical Rank

medical Degrees

Download Badge

Medical

David Webb 's Degrees

Bachelors Pharmacology University of California, Berkeley
Doctorate Clinical Pharmacology Stanford University

Why Is David Webb Influential?

(Suggest an Edit or Addition)

According to Wikipedia, David John Webb, is a British physician, scientist and clinical pharmacologist, who currently holds the Christison Chair of Therapeutics and Clinical Pharmacology at the University of Edinburgh. He was appointed to the Christison Chair of Therapeutics and Clinical Pharmacology at the University of Edinburgh in 1995, and from 1998 to 2001 he was Head of the University's Department of Medical Sciences there. He established its Centre for Cardiovascular Science in 2000.

(See a Problem?)

David Webb 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. (2014) (1401)
The influence of heart rate on augmentation index and central arterial pressure in humans (2000) (1023)
Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis (1998) (1009)
Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. (2003) (815)
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial (2015) (787)
Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. (2005) (719)
Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. (2005) (650)
Contribution of endogenous generation of endothelin-1 to basal vascular tone (1994) (635)
A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. (2007) (581)
The revision of the Declaration of Helsinki: past, present and future. (2004) (522)
Nitric Oxide Regulates Local Arterial Distensibility In Vivo (2002) (520)
Circulating microRNAs as potential markers of human drug‐induced liver injury (2011) (501)
Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. (1998) (484)
Measuring forearm blood flow and interpreting the responses to drugs and mediators. (1995) (446)
Increased central pulse pressure and augmentation index in subjects with hypercholesterolemia. (2002) (432)
Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. (1999) (413)
Pulse transit time measured from the ECG: an unreliable marker of beat-to-beat blood pressure. (2006) (409)
Pulse‐Wave Analysis: Clinical Evaluation of a Noninvasive, Widely Applicable Method for Assessing Endothelial Function (2002) (408)
Identification and proteomic profiling of exosomes in human cerebrospinal fluid (2012) (393)
Endothelin (2016) (392)
Endothelin as a regulator of cardiovascular function in health and disease (1998) (383)
Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital (2013) (380)
Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. (2001) (365)
Heart rate dependency of pulse pressure amplification and arterial stiffness. (2002) (351)
Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. (1996) (343)
Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. (1997) (342)
Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. (1996) (322)
Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. (1999) (317)
Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. (1995) (307)
Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. (1995) (307)
Vascular effects of apelin in vivo in man. (2008) (290)
Impaired Coronary Tissue Plasminogen Activator Release Is Associated With Coronary Atherosclerosis and Cigarette Smoking: Direct Link Between Endothelial Dysfunction and Atherothrombosis (2001) (279)
Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. (2001) (271)
Uric acid reduces exercise-induced oxidative stress in healthy adults. (2003) (252)
Undergraduate preparation for prescribing: the views of 2413 UK medical students and recent graduates. (2008) (244)
The endothelin system and its antagonism in chronic kidney disease. (2006) (234)
Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity in vivo. (2002) (224)
The endothelin family of peptides: local hormones with diverse roles in health and disease? (1993) (215)
Arterial stiffness and hypertension: emerging concepts. (2010) (213)
Emerging Concepts (2009) (212)
Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. (2006) (211)
Inhibition of nitric oxide synthesis increases blood pressure in healthy humans (1993) (203)
Medical students' perceptions and knowledge about antimicrobial stewardship: how are we educating our future prescribers? (2013) (200)
Endothelin-A Receptor Antagonism Reduces Blood Pressure and Increases Renal Blood Flow in Hypertensive Patients With Chronic Renal Failure: A Comparison of Selective and Combined Endothelin Receptor Blockade (2004) (200)
Uric Acid Restores Endothelial Function in Patients With Type 1 Diabetes and Regular Smokers (2006) (197)
Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. (1996) (196)
The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? (2008) (190)
Pulse wave analysis and arterial stiffness. (1998) (187)
Oxidized Phospholipid Inhibition of Toll-like Receptor (TLR) Signaling Is Restricted to TLR2 and TLR4 (2008) (184)
Increased glucocorticoid activity in men with cardiovascular risk factors. (1998) (183)
Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. (2000) (179)
Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man (2001) (174)
Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. (1998) (172)
Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. (2002) (171)
Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. (1998) (168)
Abnormal Vascular Responses to Supine Exercise in Hypertrophic Cardiomyopathy (1991) (166)
Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. (1999) (166)
Quantification of human urinary exosomes by nanoparticle tracking analysis (2013) (162)
The endothelin system and its potential as a therapeutic target in cardiovascular disease. (1996) (162)
Role of endothelin-1 in clinical hypertension: 20 years on. (2008) (161)
Endothelin is a potent long-lasting vasoconstrictor in men. (1989) (159)
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies (2018) (153)
Prevalence and Causes of Prescribing Errors: The PRescribing Outcomes for Trainee Doctors Engaged in Clinical Training (PROTECT) Study (2014) (153)
Adenoviral Gene Delivery of Elafin and Secretory Leukocyte Protease Inhibitor Attenuates NF-κB-Dependent Inflammatory Responses of Human Endothelial Cells and Macrophages to Atherogenic Stimuli1 (2004) (152)
Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial (2014) (152)
Cardiovascular Effects of Physiological and Standard Sex Steroid Replacement Regimens in Premature Ovarian Failure (2009) (146)
Studies with iontophoretic administration of drugs to human dermal vessels in vivo: cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide. (1998) (143)
Learning curves, taking instructions, and patient safety: using a theoretical domains framework in an interview study to investigate prescribing errors among trainee doctors (2012) (143)
Selective Endothelin-A Receptor Antagonism Reduces Proteinuria, Blood Pressure, and Arterial Stiffness in Chronic Proteinuric Kidney Disease (2011) (140)
A prescription for better prescribing (2006) (140)
Blood Markers of Coagulation, Fibrinolysis, Endothelial Dysfunction and Inflammation in Lacunar Stroke versus Non-Lacunar Stroke and Non-Stroke: Systematic Review and Meta-Analysis (2013) (138)
Seasonal variation in glucocorticoid activity in healthy men. (1997) (137)
Endothelins in cardiovascular biology and therapeutics (2019) (133)
Increased augmentation index and systolic stress in type 1 diabetes mellitus. (2000) (131)
Profile of Past and Current Clinical Trials Involving Endothelin Receptor Antagonists: The Novel “-Sentan” Class of Drug (2006) (130)
Endothelin: new discoveries and rapid progress in the clinic. (1998) (129)
Peripheral endothelial dysfunction in normal pressure glaucoma. (1999) (128)
Bradykinin Contributes to the Vasodilator Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure (2001) (128)
Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. (1998) (127)
Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man. (1992) (126)
Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans (2005) (125)
Cortisol inhibits cholinergic vasodilation in the human forearm. (2000) (124)
Long‐term adverse effects of paracetamol – a review (2018) (124)
Perceived causes of prescribing errors by junior doctors in hospital inpatients: a study from the PROTECT programme (2012) (123)
Exosomal transmission of functional aquaporin 2 in kidney cortical collecting duct cells (2011) (122)
Activation of endothelin ETA receptors masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric arteries (1997) (120)
Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom (2015) (119)
Cardiovascular Effects of Acute Oxygen Administration in Healthy Adults (2003) (118)
Blood Pressure-Independent Reduction in Proteinuria and Arterial Stiffness After Acute Endothelin-A Receptor Antagonism in Chronic Kidney Disease (2009) (118)
Measurement of plasma angiotensin II. (1985) (117)
Oral vitamin C reduces arterial stiffness and platelet aggregation in humans. (1999) (117)
Effects of short-term isocapnic hyperoxia and hypoxia on cardiovascular function. (2006) (113)
Contribution of parental blood pressures to association between low birth weight and adult high blood pressure: cross sectional study (1998) (113)
Endothelium-derived endothelin-1 (2010) (112)
Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. (1993) (111)
Effect of the UK’s revised paracetamol poisoning management guidelines on admissions, adverse reactions and costs of treatment (2014) (111)
Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial. (2009) (110)
Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. (2000) (110)
Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. (2000) (108)
Deletion of Endothelial Cell Endothelin B Receptors Does Not Affect Blood Pressure or Sensitivity to Salt (2006) (108)
An in vivo Model for the Assessment of Acute Fibrinolytic Capacity of the Endothelium (1997) (107)
Nebivolol Increases Arterial Distensibility In Vivo (2004) (107)
Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1. (1994) (104)
Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention. (2008) (101)
Effect of Regular Phosphodiesterase Type 5 Inhibition in Hypertension (2006) (100)
The pharmacology of human blood vessels in vivo. (1995) (100)
High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. (2002) (97)
Salmeterol for the prevention of high-altitude pulmonary edema. (2002) (94)
Non-invasive measures of pulse wave velocity correlate with coronary arterial plaque load in humans (2004) (93)
Effects of antiplatelet components of tomato extract on platelet function in vitro and ex vivo: a time-course cannulation study in healthy humans. (2006) (92)
Endothelin antagonism in pulmonary hypertension, heart failure, and beyond (2005) (90)
Uric acid as a risk factor for cardiovascular disease. (2000) (90)
Effects of tomato extract on platelet function: a double-blinded crossover study in healthy humans. (2006) (89)
Oxygen therapy in acute medical care (2002) (88)
Systemic ETA receptor antagonism with BQ‐123 blocks ET‐1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men (2001) (88)
Raised plasma endothelin in unstable angina and non-Q wave myocardial infarction: relation to cardiovascular outcome. (1994) (87)
Renin and atrial natriuretic peptide restriction fragment length polymorphisms: association with ethnicity and blood pressure. (1991) (87)
A prescription for better prescribing (2006) (86)
Nitric oxide donor drugs: current status and future trends (2002) (84)
Local L-NG-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm. (1994) (84)
11β-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice. (2011) (84)
Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. (2014) (83)
Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence (2005) (83)
Endogenous urate production augments plasma antioxidant capacity in healthy lowland subjects exposed to high altitude. (2007) (82)
Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products. (2006) (81)
Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial (2016) (80)
Hyperuricaemia does not impair cardiovascular function in healthy adults (2004) (80)
Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. (1995) (77)
Acute caffeine intake influences central more than peripheral blood pressure in young adults. (2003) (76)
Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus nephritis. (2009) (76)
Microvascular correlates of blood pressure, plasma glucose, and insulin resistance in health. (2002) (74)
Selective and mixed endothelin receptor antagonism in cardiovascular disease. (2007) (74)
Effect of polyphenol-rich grape seed extract on ambulatory blood pressure in subjects with pre- and stage I hypertension (2013) (74)
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double‐Blind Randomized Controlled Trial (2017) (73)
Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity. (2011) (73)
The increase in human plasma immunoreactive endothelin but not big endothelin‐1 or its C‐terminal fragment induced by systemic administration of the endothelin antagonist TAK‐044 (1996) (71)
Cyclophilin A Is a Damage-Associated Molecular Pattern Molecule That Mediates Acetaminophen-Induced Liver Injury (2011) (71)
Impairment of forearm vasodilatation to acetylcholine in hypercholesterolemia is reversed by aspirin. (1998) (70)
Leptin Induces Hypertension and Endothelial Dysfunction via Aldosterone-Dependent Mechanisms in Obese Female Mice (2016) (69)
Vessel wall stiffness in type 1 diabetes and the central hemodynamic effects of acute hypoglycemia. (2007) (69)
S‐Nitrosothiols cause prolonged, nitric oxide‐mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery (2000) (68)
Clinical pharmacology—too young to die? (2006) (67)
Endothelin: from molecule to man. (2003) (67)
L-NMMA Increases blood pressure in man (1993) (66)
The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man. (1998) (66)
Physiological role of nitric oxide in regulation of renal function in humans. (1997) (65)
Endothelin‐1 and the kidney – beyond BP (2012) (65)
No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. (2002) (64)
Altered endothelin-1 vasoreactivity in patients with untreated normal-pressure glaucoma. (2006) (64)
Measurement of renal function in patients with chronic kidney disease (2013) (64)
Peripheral vascular tone in patients with cirrhosis: role of the renin-angiotensin and sympathetic nervous systems. (1998) (64)
The Trevor Howell Lecture. Age, arterial stiffness and the endothelium. (1997) (63)
Clinical Trials of Endothelin Antagonists in Heart Failure: A Question of Dose? (2006) (63)
Clinical Potential of Combined Organic Nitrate and Phosphodiesterase Type 5 Inhibitor in Treatment-Resistant Hypertension (2010) (63)
Phosphoramidon inhibition of the in vivo conversion of big endothelin‐1 to endothelin‐1 in the human forearm (1995) (62)
Chorioretinal thinning in chronic kidney disease links to inflammation and endothelial dysfunction (2016) (62)
COX-2 selective inhibitors—important lessons learned (2005) (62)
Endothelin receptors cloned, endothelin converting enzyme characterized and pathophysiological roles for endothelin proposed. (1991) (61)
Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease[S] (2015) (61)
Endothelin: progress in pharmacology and physiology. (1993) (60)
Modelling estimates of the burden of respiratory syncytial virus infection in children in the UK (2016) (59)
Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. (2001) (58)
Adrenomedullin (ADM) in the human forearm vascular bed: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP). (2001) (58)
Endothelium-dependent modulation of responses to endothelin-I in human veins. (1993) (57)
Contribution of Endothelin 1 to the Vascular Effects of Diesel Exhaust Inhalation in Humans (2009) (56)
Ultrasound findings in renal parenchymal disease: comparison with histological appearances. (1994) (54)
Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. (2004) (54)
Endothelin signalling mediates experience-dependent myelination in the CNS (2019) (54)
Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study (2016) (53)
Urinary peptidomics in a rodent model of diabetic nephropathy highlights epidermal growth factor as a biomarker for renal deterioration in patients with type 2 diabetes. (2016) (53)
Oestrogen and the cardiovascular system: the good, the bad and the puzzling. (2001) (52)
Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. (2007) (52)
Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. (2000) (52)
Assessing and addressing cardiovascular risk in adults with Turner syndrome (2013) (51)
Cough associated with captopril and enalapril. (1987) (51)
Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. (1996) (51)
Developing a core curriculum in clinical pharmacology and therapeutics: a Delphi study. (2003) (50)
Bradykinin Contributes to the Systemic Hemodynamic Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure (2004) (50)
Non-enterobacterial endotoxins stimulate human coronary artery but not venous endothelial cell activation via Toll-like receptor 2. (2007) (50)
Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment. (1991) (49)
Metabolic parameters associated with arterial stiffness in older adults with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study (2013) (49)
Non-invasive measurement of cardiac output in patients with chronic heart failure (2004) (49)
Diurnal Variation in Blood Pressure and Arterial Stiffness in Chronic Kidney Disease: The Role of Endothelin-1 (2014) (49)
Implications of the BIA‐102474‐101 study for review of first‐into‐human clinical trials (2016) (49)
Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. (1997) (49)
Altered peripheral vascular responses to exogenous and endogenous endothelin‐1 in patients with well‐compensated cirrhosis (2001) (48)
Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease (2019) (48)
Comparison of forearm vasodilatation to substance P and acetylcholine: contribution of nitric oxide. (1997) (48)
Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography (2000) (48)
Angiotensin II augments sympathetically mediated arteriolar constriction in man. (1991) (48)
Reduced responsiveness to endothelin-1 in peripheral resistance vessels of patients with syndrome X. (1998) (47)
A comparison of techniques to assess skin blanching following the topical application of glucocorticoids (1996) (47)
Endothelin receptor antagonism in patients with chronic heart failure. (2000) (47)
25-Hydroxycholesterol, 7β-hydroxycholesterol and 7-ketocholesterol upregulate interleukin-8 expression independently of Toll-like receptor 1, 2, 4 or 6 signalling in human macrophages (2007) (46)
Prescribing Safety Assessment 2016: Delivery of a national prescribing assessment to 7343 UK final‐year medical students (2017) (46)
Educating European (junior) doctors for safe prescribing. (2007) (46)
N‐substituted analogues of S‐nitroso‐N‐acetyl‐D,L‐penicillamine: chemical stability and prolonged nitric oxide mediated vasodilatation in isolated rat femoral arteries (1999) (46)
Glucocorticoids Induce Nondipping Blood Pressure by Activating the Thiazide-Sensitive Cotransporter (2016) (45)
Impact of a focussed teaching programme on practical prescribing skills among final year medical students. (2009) (45)
Toll-like receptor 4 signalling is neither sufficient nor required for oxidised phospholipid mediated induction of interleukin-8 expression. (2007) (45)
Management of chronic heart failure due to systolic left ventricular dysfunction by cardiologist and non‐cardiologist physicians (2003) (44)
Nitric oxide in liver failure (1991) (44)
Junior doctors' perceptions of their self-efficacy in prescribing, their prescribing errors and the possible causes of errors. (2013) (44)
Characteristics of P2 (nucleotide) receptors mediating contraction and relaxation of rat aortic strips: possible physiological relevance. (1985) (44)
A systematic review of the effect of paracetamol on blood pressure in hypertensive and non‐hypertensive subjects (2013) (43)
Prescribing safety: ensuring that new graduates are prepared (2015) (43)
Vasopressin Regulates Extracellular Vesicle Uptake by Kidney Collecting Duct Cells. (2016) (42)
Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial (2017) (42)
Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide (2003) (42)
Prolonged effect of a novel S‐nitrosated glyco‐amino acid in endothelium‐denuded rat femoral arteries: potential as a slow release nitric oxide donor drug (1997) (42)
Inhibition of human platelet aggregation by a novel S‐nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti‐thrombotic therapy (2000) (41)
The eye, the kidney, and cardiovascular disease: old concepts, better tools, and new horizons (2020) (41)
Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial (2006) (40)
Nitric oxide mediates the reduced vasoconstrictor response to angiotensin II in patients with preascitic cirrhosis. (2003) (40)
The relationship between blood pressure and left ventricular mass in essential hypertension is observed only in the presence of the angiotensin-converting enzyme gene deletion allele. (1994) (40)
Interaction of Neuropeptide Y and the Sympathetic Nervous System in Vascular Control in Man John Clarke, MRCPI; (1991) (40)
Endogenous Endothelin-1 Limits Exercise-Induced Vasodilation in Hypertensive Humans (2002) (40)
Aortic pulse-wave velocity (1999) (39)
Activation of the endothelin system in insulin resistance. (2001) (39)
Pharmacokinetics, Safety and Tolerance of Voriconazole in Renally Impaired Subjects (2008) (39)
Acute Methionine Loading Does not Alter Arterial Stiffness in Humans (2001) (38)
Core content of a course in clinical pharmacology. (2003) (38)
Direct Vascular Effects of Protease-Activated Receptor Type 1 Agonism In Vivo in Humans (2006) (37)
Reduced endogenous endothelin-1-mediated vascular tone in chronic renal failure. (1999) (37)
The availability of prescription-only analgesics purchased from the internet in the UK. (2009) (36)
Plasma endothelin concentrations in hypertension. (2000) (36)
Multi-layered Spatial Transcriptomics Identify Secretory Factors Promoting Human Hematopoietic Stem Cell Development (2020) (36)
ENALAPRIL-INDUCED COUGH (1986) (36)
Angiotensin II augments sympathetically induced venoconstriction in man. (1988) (35)
Influenza-attributable burden in United Kingdom primary care (2015) (35)
Aortic dissection in children and adolescents with Turner syndrome: risk factors and management recommendations (2015) (35)
Blood glucose monitors: a laboratory and patient assessment. (1980) (35)
Pharmacology of endothelin-1 in vivo in humans. (1991) (35)
Role of calcitonin gene-related peptide in cerebral vasospasm, and as a therapeutic approach to subarachnoid hemorrhage (2012) (35)
Safety and Efficacy of the SNAP 12-hour Acetylcysteine Regimen for the Treatment of Paracetamol Overdose (2019) (35)
Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man. (1999) (35)
Novel S-nitrosothiols do not engender vascular tolerance and remain effective in glyceryltrinitrate-tolerant rat femoral arteries. (2000) (34)
Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD. (2013) (34)
Endothelins are potent vasoconstrictors, and much more besides. (2000) (33)
The effect of oxidative stress on endothelium-dependent and nitric oxide donor-induced relaxation: implications for nitrate tolerance. (2002) (33)
Urotensin II: a new mediator in cardiopulmonary regulation? (2001) (33)
Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans. (2008) (33)
Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo-controlled trial. (2011) (33)
Sympathetically mediated vasoconstriction is augmented by angiotensin II in man (1988) (33)
Potential Therapeutic Role of Phosphodiesterase Type 5 Inhibition in Hypertension and Chronic Kidney Disease (2014) (33)
Forearm Vasoconstriction to Endothelin‐1 Is Mediated by ETA and ETB Receptors In Vivo in Humans (1995) (33)
Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo (2002) (32)
Clinical experience with endothelin antagonists. (1998) (32)
The Endothelin System in Cardiovascular Physiology and Pathophysiology (1997) (32)
Vascular responses to local atrial natriuretic peptide infusion in man. (1988) (32)
Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations. (2014) (31)
Ethanol consumption produces a small increase in circulating miR-122 in healthy individuals (2016) (30)
Scottish and Newcastle Antiemetic Pre-treatment for paracetamol poisoning study (SNAP) (2013) (30)
Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery (1999) (30)
Endothelin Antagonism and Its Role in the Treatment of Hypertension (2013) (30)
Imaging of cardiovascular risk in patients with Turner's syndrome (2015) (29)
Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in males (1995) (29)
Risk Factors for Metabolic Syndrome Independently Predict Arterial Stiffness and Endothelial Dysfunction in Patients With Chronic Kidney Disease and Minimal Comorbidity (2012) (29)
Chronic Administration of Losartan, an Angiotensin II Receptor Antagonist, is not Effective in Reducing Portal Pressure in Patients with Preascitic Cirrhosis (2004) (29)
Value-based pricing of drugs in the UK (2007) (29)
Renal function is associated with arterial stiffness and predicts outcome in patients with coronary artery disease. (2008) (29)
Endogenous angiotensin II contributes to basal peripheral vascular tone in sodium deplete but not sodium replete man. (1997) (28)
Venoconstriction to endothelin-1 in humans: role of calcium and potassium channels. (1993) (28)
Endogenous endothelin generation maintains vascular tone in humans. (1995) (28)
Age, arterial stiffness and the endothelium (1997) (27)
Low Birth Weight Predicts Higher Blood Pressure But Not Dermal Capillary Density in Two Populations (2004) (27)
Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients (2008) (27)
Morphine is an arteriolar vasodilator in man. (2009) (27)
Arterial blood pressure and stiffness in hypertension: is arterial structure important? (2006) (27)
Acute Endothelin-A Receptor Antagonism Prevents Normal Reduction of Myocardial Ischemia on Repeated Balloon Inflations During Angioplasty (2000) (27)
Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II (1998) (27)
Vitamin C Has No Effect on Endothelium-Dependent Vasomotion and Acute Endogenous Fibrinolysis in Healthy Smokers (2004) (26)
Effects of endothelin receptor antagonism relate to the degree of renin-angiotensin system blockade in chronic proteinuric kidney disease. (2009) (26)
New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension (2016) (26)
Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series (2016) (26)
Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: A double-blind, placebo-controlled, randomized, crossover trial* (2007) (26)
Risk of solid organ transplant rejection following vaccination with seasonal trivalent inactivated influenza vaccines in England: A self-controlled case-series. (2016) (25)
A novel role for myeloid endothelin-B receptors in hypertension (2019) (25)
Tissue angiotensin generation and regulation of vascular tone. (1995) (25)
Peripheral vascular structure and function in men with contrasting GH levels. (2002) (24)
The road from AKI to CKD: the role of endothelin. (2013) (24)
Effects of acute methionine loading and vitamin C on endogenous fibrinolysis, endothelium-dependent vasomotion and platelet aggregation. (2001) (24)
Electrocardiographic left ventricular hypertrophy in type 1 diabetes: prevalence and relation to coronary heart disease and cardiovascular risk factors: the Eurodiab IDDM Complications Study. (2005) (24)
Ultraviolet A radiation and COVID‐19 deaths in the USA with replication studies in England and Italy* (2020) (24)
DORADO: opportunity postponed: lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension. (2010) (24)
Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's disease. (1999) (24)
Comparison of two plethysmography systems in assessment of forearm blood flow. (2004) (23)
Vascular Endothelium in Human Physiology and Pathophysiology (2000) (23)
A generalized arterial transfer function derived at rest underestimates augmentation of central pressure after exercise (2007) (23)
Physiological role of the endothelin system in human cardiovascular and renal haemodynamics. (1997) (22)
The effect of intra-arterial endothelin on resting blood flow and sympathetically mediated vasoconstriction in the forearm of man. (1991) (22)
Augmentation index assessed by applanation tonometry is elevated in Marfan Syndrome (2007) (22)
Edinburgh Research Explorer Oxidized phospholipid inhibition of Toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4 - Roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition (2017) (22)
Quantitative 3-Dimensional Imaging of Murine Neointimal and Atherosclerotic Lesions by Optical Projection Tomography (2011) (22)
Direct comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure (2005) (22)
Bradykinin Receptor Antagonism and Endothelial Tissue Plasminogen Activator Release in Humans (2003) (22)
Impact on hypertension control of a patient-held guideline: a randomised controlled trial. (2006) (22)
Value-based medicine pricing: NICE work? (2011) (22)
Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency. (2008) (22)
Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease (2003) (22)
Mechanisms for an effect of acetylcysteine on renal function after exposure to radio-graphic contrast material: study protocol (2012) (22)
Endothelins and their inhibition in the human skin microcirculation: ET[1-31], a new vasoconstrictor peptide. (2004) (22)
Sildenafil improves renal function in patients with pulmonary arterial hypertension. (2015) (21)
REDUCTION OF BLOOD PRESSURE IN MAN WITH H-142, A POTENT NEW RENIN INHIBITOR (1983) (21)
Platelet aggregation in young men with contrasting predisposition to high blood pressure. (1999) (21)
Disease mongering -- a challenge for everyone involved in healthcare. (2007) (21)
Coronary vasoconstriction after coronary angioplasty is attenuated by endothelin a receptor antagonism. (2001) (21)
Enhanced basal nitric oxide production in heart failure. (1994) (21)
Short-term effects of transdermal nicotine on acute tissue plasminogen activator release in vivo in man. (2001) (21)
Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: General mechanisms a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and The Japanese Society of Hypertension (2017) (21)
Endothelin antagonists and hypertension: a question of dose? (2002) (21)
Plasma endothelin following cardiac arrest: differences between survivors and non-survivors. (1994) (20)
Activation of the endothelin B receptor causes a dose-dependent accumulation of cyclic GMP in human platelets. (1996) (20)
Molecular Biology and Pharmacology of the Endothelins (1995) (19)
Venous endothelin receptor function in patients with chronic heart failure. (2000) (19)
Extracellular Nitric Oxide Release Mediates Soluble Guanylate Cyclase-Independent Vasodilator Action of Spermine NONOate: Comparison with Other Nitric Oxide Donors in Isolated Rat Femoral Arteries (2004) (19)
Therapeutic potential of endothelin receptor antagonism in kidney disease. (2016) (19)
Endothelins come of age (1993) (19)
Repeatability of local forearm vasoconstriction to endothelin-1 measured by venous occlusion plethysmography. (2002) (18)
Localization and function of ET‐1 and ET receptors in small arteries post‐myocardial infarction: Upregulation of smooth muscle ETB receptors that modulate contraction (2000) (18)
Endothelial nitric oxide synthase polymorphisms do not influence pulmonary artery systolic pressure at altitude. (2006) (18)
Validation of laser Doppler flowmetry coupled with intra-dermal injection for investigating effects of vasoactive agents on the skin microcirculation in man (2003) (18)
Regular Acetaminophen Use and Blood Pressure in People With Hypertension: The PATH-BP Trial. (2022) (17)
Endothelin as a natriuretic hormone: the case for a paracrine action mediated by nitric oxide. (2001) (17)
Augmentation of sympathetic venoconstriction by angiotensin II in human dorsal hand veins. (1989) (17)
The potassium channel opening drug cromakalim produces arterioselective vasodilation in the upper limbs of healthy volunteers. (1989) (17)
Fractional urinary excretion of endothelin-1 is reduced by acute ETB receptor blockade. (2007) (17)
Severe thiazide-induced hyponatraemia during treatment with enalapril. (1987) (17)
The endothelin system in cardiovascular disease (1997) (17)
Sildenafil for “blue babies” (2002) (17)
Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun? (2010) (17)
Similar blood pressure but different outcome in rats with DOC and post-DOC hypertension. (1983) (17)
Endothelium‐Dependent Modulation of Venoconstriction to Sarafotoxin S6c in Human Veins In Vivo (1995) (17)
The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment. (2007) (17)
Characterization of Triptolide-Induced Hepatotoxicity by Imaging and Transcriptomics in a Novel Zebrafish Model (2017) (17)
A novel S‐nitrosothiol (RIG200) causes prolonged relaxation in dorsal hand veins with damaged endothelium (2000) (17)
Systemic and regional changes in plasma endothelin following transient increase in portal pressure (2003) (17)
Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice. (2012) (16)
Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: Role in disease conditions a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension (2017) (16)
Similarity between the suprasystolic wideband external pulse wave and the first derivative of the intra-arterial pulse wave. (2007) (16)
Endothelial dysfunction in patients with recent myocardial infarction and hyperhomocysteinaemia: effects of vitamin supplementation. (2005) (16)
The peptide endothelin receptor antagonist, TAK-044, produces sustained inhibition of endothelin-1 mediated arteriolar vasoconstriction. (2003) (16)
Regulation of regional vascular tone: the role of angiotensin conversion in human forearm resistance vessels. (1988) (16)
Forearm vasoconstriction to endothelin-1 is impaired, but constriction to sarafotoxin 6c and vasodilatation to BQ-123 unaltered, in patients with essential hypertension. (2002) (16)
Contribution of the M3 muscarinic receptors to the vasodilator response to acetylcholine in the human forearm vascular bed. (2008) (15)
Time-dependent interactions of the hypotensive effects of sildenafil citrate and sublingual glyceryl trinitrate. (2009) (15)
Circulating plasma cortisol concentrations are not associated with coronary artery disease or peripheral vascular disease. (2009) (15)
Absence of Ca2+-stimulated adenylyl cyclases leads to reduced synaptic plasticity and impaired experience-dependent fear memory (2012) (15)
Novel S-nitrosothiols do not engender vascular tolerance and remain effective in glyceryl trinitrate-tolerant rat femoral arteries. (2000) (15)
Chronotherapy in hypertension: the devil is in the details. (2020) (15)
Uric acid concentrations and the mechanisms of cardiovascular disease. (2002) (15)
Chronic selective endothelin A receptor antagonism reduces serum uric acid in hypertensive chronic kidney disease. (2011) (15)
No adverse hemodynamic interaction between sildenafil and red wine (2004) (15)
Constriction to ETB receptor agonists, BQ-3020 and sarafotoxin s6c, in human resistance and capacitance vessels in vivo. (2000) (15)
A novel S-nitrosothiol causes prolonged and selective inhibition of platelet adhesion at sites of vascular injury. (2003) (15)
Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension (2015) (14)
Venoconstriction to endothelin-1 in humans is attenuated by local generation of prostacyclin but not nitric oxide. (1993) (14)
Enhanced basal nitric oxide production in heart failure (1994) (14)
Improving medication safety: focus on prescribers and systems (2019) (14)
Prognosis without treatment as a modifier in health economic assessments (2005) (14)
Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease (2019) (14)
Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Endothelin antagonism in heart failure. (1995) (14)
A spoonful of sugar? Tomorrow's doctors 2002. (2002) (14)
Endothelin in nondiabetic chronic kidney disease: preclinical and clinical studies. (2015) (14)
Effect of Cold Exposure, Exercise and High Altitude on Plasma Endothelin-1 and Endothelial Cell Markers in Man (1999) (13)
Plasma Pro‐Endothelin‐1 Peptide Concentrations Rise in Chronic Kidney Disease and Following Selective Endothelin A Receptor Antagonism (2015) (13)
Abnormal endothelin B receptor vasomotor responses in patients with Hirschsprung's disease. (2002) (13)
Non-endothelial cell endothelin-B receptors limit neointima formation following vascular injury. (2012) (13)
515 MECHANISTIC BIOMARKERS PROVIDE EARLY AND SENSITIVE DETECTION OF PARACETAMOL-INDUCED ACUTE LIVER INJURY AT FIRST PRESENTATION TO HOSPITAL (2013) (13)
Dose‐response Relationship of Sublingual Nitroglycerin with Brachial Artery Dilatation and Change in Central and Peripheral Augmentation Index (2005) (13)
Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men. (2013) (13)
Local and Systemic Effects of Intra-arterial Desmopressin in Healthy Volunteers and Patients with Type 3 von Willebrand Disease (2000) (13)
Are Selective Endothelin A Receptor Antagonists Better than Mixed Antagonists? (2001) (13)
Influence of ramipril diacid on the peripheral vascular effects of angiotensin I. (1987) (13)
Greater Functional ETB Receptor Antagonism With Bosentan Than Sitaxsentan in Healthy Men (2010) (13)
Comparative effects of glyceryl trinitrate and amyl nitrite on pulse wave reflection and augmentation index. (2005) (13)
Intra‐arterial vasopressin in the human forearm: pharmacodynamics and the role of nitric oxide (2003) (13)
PLASMA IMMUNOREACTIVE ENDOTHELIN IN URAEMIA (1989) (13)
Sodium–Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies (2021) (12)
The Influence of Primary Care Prescribing Rates for New Drugs on Spontaneous Reporting of Adverse Drug Reactions (2007) (12)
Effects of candesartan on cardiac and arterial structure and function in hypertensive subjects (2001) (12)
Dietary sodium deprivation raises blood pressure in the rat but does not produce irreversible hyperaldosteronism. (1987) (12)
Basal endothelial nitric oxide production and insulin sensitivity are positively related in man (1995) (11)
Cardiovascular disease biomarkers are associated with declining renal function in type 2 diabetes (2017) (11)
Endothelin antagonism in patients with nondiabetic chronic kidney disease. (2011) (11)
Regulation of the myocardial endothelin system by angiotensin-II and losartan. (2000) (11)
??White-coat?? hypertension: a comparison of detection using ambulatory blood pressure monitoring or home monitoring of blood pressure (1996) (11)
Histamine-induced vasodilatation in the human forearm vasculature. (2013) (11)
Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals. (2020) (11)
Functional studies in small arteries do not support a primary role for endothelin in the pathogenesis of Raynaud's disease. (1998) (11)
THE PREVALENCE OF PRESCRIBING ERRORS AMONGST JUNIOR DOCTORS IN SCOTLAND (2011) (10)
Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial (2015) (10)
Bosentan in essential hypertension. (1998) (10)
Smooth Muscle Endothelin B Receptors Regulate Blood Pressure but Not Vascular Function or Neointimal Remodeling (2017) (10)
A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial (2017) (10)
An investigation into the direct and indirect venoconstrictor effects of endothelin-1 and big endothelin-1 in man. (1995) (10)
A new class of NO-donor pro-drugs triggered by γ-glutamyl transpeptidase with potential for reno-selective vasodilatation. (2013) (10)
Internet pharmacy: a web of mistrust? (2008) (10)
Lithium carbonate as a potential pharmacological vehicle: intravenous kinetics of single-dose administration in healthy subjects (2002) (10)
Poor prescribing is continual (2006) (10)
Cyclic GMP protects human macrophages against peroxynitrite-induced apoptosis (2009) (10)
Selectivity of NSAIDs for COX-2 and cardiovascular outcome. (2006) (10)
Regarding the accuracy of generalized transfer functions for estimating central aortic blood pressure when calibrated non‐invasively (2000) (10)
The potassium channel opener BRL 38227 inhibits binding of [125I]-labelled endothelin-1 to rat cardiac membranes. (1992) (10)
Vascular angiotensin conversion in humans. (1986) (10)
The effect of local converting enzyme inhibition on the dilator response to substance P in the human forearm. (1990) (10)
Reduced venous responsiveness to endothelin-1 but not noradrenaline in hypertensive chronic renal failure. (2001) (10)
Impaired effect of endothelin-1 on coronary artery stiffness in type 2 diabetes. (2006) (9)
Electrophysiologic Effects of Endothelin Receptor–A Blockade in Patients with Coronary Artery Disease (2003) (9)
Effects of salbutamol and glyceryl trinitrate on large arterial stiffness are similar between patients with hypertension and adults with normal blood pressure. (2006) (9)
Endothelin: a long-acting local constrictor hormone. (1992) (9)
Impaired pressure natriuresis and non‐dipping blood pressure in rats with early type 1 diabetes mellitus (2018) (9)
Clinical pharmacology and therapeutics in a changing world. (1999) (9)
Attending a social event and consuming alcohol is associated with changes in serum microRNA: a before and after study in healthy adults (2018) (9)
Sitaxsentan sodium for pulmonary hypertension. (2008) (9)
Retinal fingerprints for precision profiling of cardiovascular risk (2019) (9)
EVIDENCE FOR AN ABNORMAL VASODILATOR RESPONSE IN HYPERTROPHIC CARDIOMYOPATHY (1989) (9)
The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processes. (2008) (9)
Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease (2021) (9)
An investigation into the effect of advice from the Scottish Medicines Consortium on the use of medicines in Scotland's Health Service. (2011) (9)
Pericardial effusions in healthy lowlanders after acute ascent to high altitude (2005) (9)
New guidelines for drive-by renal arteriography may lead to an unjustifiable increase in percutaneous intervention (2006) (9)
The three official language versions of the Declaration of Helsinki: what’s lost in translation? (2007) (8)
Endothelin-1 and aggregation of human platelets in vitro. (1993) (8)
Peripheral augmentation index: shouldering the central pressure load. (2008) (8)
Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension (2015) (8)
The Effect of Cerivastatin Therapy on Vascular Responses to Endothelin Antagonists in Humans (2004) (8)
Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease (2020) (8)
Endothelin-1 Mediates the Systemic and Renal Hemodynamic Effects of GPR81 Activation (2020) (8)
Pharmacoepidemiology: Using randomised control trials and observational studies in clinical decision‐making (2019) (8)
Physician Opinions on the Implementation of the Sign Guideline for Heart Failure (2004) (8)
Scottish Medicines Consortium: an Overview of Rapid New Drug Assessment in Scotland. (2007) (8)
Acute endothelin(A) receptor antagonism improves coronary artery compliance in coronary artery disease patients. (2002) (7)
Endothelial Dysfunction and Hypertension (2012) (7)
S-nitrosothiols for nitrate tolerance (1999) (7)
PREDICTIVE VALUE OF PULSE WAVE VELOCITY FOR CARDIOVASCULAR EVENTS IN 15220 SUBJECTS: AN INDIVIDUAL PARTICIPANT META-ANALYSIS ON BEHALF OF THE PWV COLLABORATIVE GROUP: HT.3.03 (2010) (7)
Vasodilator effects of the endothelin ET receptor selective antagonist BMS-193884 in healthy men. (2005) (7)
Development and characterization of glutamyl-protected N-hydroxyguanidines as reno-active nitric oxide donor drugs with therapeutic potential in acute renal failure. (2013) (7)
Translational research: a priority for health and wealth (2010) (7)
Rationale and Design of the Genotype-Blinded Trial of Torasemide for the Treatment of Hypertension (BHF UMOD) (2020) (7)
Macrophages to Atherogenic Stimuli Responses of Human Endothelial Cells and B-Dependent Inflammatory κ Attenuates NF-Secretory Leukocyte Protease Inhibitor Adenoviral Gene Delivery of Elafin and Kotelevtsev and (2004) (7)
Monitoring ambulatory blood pressure in general practice. (1992) (7)
One standard, not two (2003) (7)
Small interfering RNA (siRNA): discovery, pharmacology and clinical development - an introductory review. (2022) (7)
Endothelin-receptor antagonism: the future is bright (2008) (7)
What is the best method of proteinuria measurement in clinical trials of endothelin receptor antagonists? (2012) (7)
An anatomically unbiased approach for analysis of renal BOLD magnetic resonance images. (2013) (7)
Plasma endothelin levels and outcome in patients undergoing repair of ruptured infrarenal abdominal aortic aneurysm. (2001) (7)
Arterial stiffness & Sri Lankan chronic kidney disease of unknown origin (2016) (7)
Endothelin Receptor Antagonists (1999) (6)
Differential vasoactive response to endothelin receptor antagonists and prostacyclin in patients with severe pulmonary hypertension. (2002) (6)
RENAL DISEASE IS ASSOCIATED WITH ACCELERATED VASCULAR AGEING: INITIAL RESULTS OF THE UK RESEARCH ALLIANCE INTO KIDNEY DISEASE AND ARTERIAL STIFFNESS (UREKA) COLLABORATION: 8A.02 (2010) (6)
Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial (2017) (6)
Endothelial Function in Hypertension (1997) (6)
The Role of Endothelin-1 in Cardiovascular Physiology and Pathophysiology (1995) (6)
Clinical and Biochemical Effects of the Renin Inhibitor H142 in Humans (1987) (6)
Human renin inhibitors. (1985) (6)
Endothelin-1[1-31] is Not Elevated in Men with Chronic Heart Failure (2004) (6)
The role of endothelin-1 in pressure autoregulation of cerebral blood flow in rats (1999) (6)
Background incidence of liver chemistry abnormalities in pediatric clinical trials for conditions with and without underlying liver disease. (2012) (6)
Endothelin receptor antagonists. Promising new agents in the management of cardiovascular disorders. (1999) (6)
First-in-Man Demonstration of Direct Endothelin-Mediated Natriuresis and Diuresis (2017) (6)
The UK's NHS and pharma: need for more clinical pharmacologists (2009) (5)
Ambrisentan and its role in the management of pulmonary arterial hypertension. (2008) (5)
A nonradioactive method for localization of endothelin receptor mRNA in situ. (1998) (5)
Influence of scanning frequency and ultrasonic contrast agent on reproducibility of left ventricular measurements in the mouse. (2005) (5)
GMC's guidance may inhibit research (2001) (5)
Deletion of the myeloid endothelin-B receptor confers long-term protection from angiotensin II-mediated kidney, eye and vessel injury (2020) (5)
B046: Increased arterial stiffness assessed by pulse wave analysis in patients with hypercholesterolaemia (2000) (5)
GEMS–RCPSG: ‘Is Academic Medicine for Me?’ National Conference 2011, 19 November 2011 (2012) (5)
Endogenous angiotensin II does not contribute to sympathetic venoconstriction in dorsal hand veins of healthy humans (1997) (5)
Big endothelin‐3 constricts forearm resistance vessels but not hand veins in humans (2000) (5)
The effect of local angiotensin converting enzyme inhibition on the action of atrial natriuretic peptide in the human forearm. (1989) (5)
The reproducibility of augmentation index measured using pulse wave analysis (1998) (5)
The Clinical Potential of Endothelin Receptor Antagonists in Cardiovascular Medicine (2012) (5)
De‐risking Clinical Trials: The BIAL Phase I Trial in Foresight (2021) (5)
Endothelin-1 does not contribute to the release of tissue plasminogen activator in vivo in man (1999) (4)
Selective endothelin B receptor blockade does not influence BNP-induced natriuresis in man. (2006) (4)
Captopril in congestive cardiac failure. (1989) (4)
chapter 31 – Mechanisms and Molecular Pathways in Hypertension (2004) (4)
Peptide histidine valine: its haemodynamic actions and pharmacokinetics in man differ from those of vasoactive intestinal peptide and peptide histidine methionine. (1990) (4)
Responses to angiotensin with and without angiotensin-converting enzyme inhibition in the canine left anterior descending coronary artery. (1993) (4)
UK Health Technology Assessment and Value Based Pricing (2015) (4)
Endothelin and blood pressure regulation. (1996) (4)
The Renin—Angiotensin Converting Enzyme Cascade: Renin and blood pressure (1984) (4)
Clinical toxicologists: the poison specialists (2016) (4)
Ultraviolet A Radiation and COVID-19 Deaths: A Multi Country Study (2020) (4)
UK medicines policy: the role of clinical pharmacologists. (2012) (4)
Nitrate resistance in platelets from patients with stable angina pectoris. (2000) (4)
Renin and blood pressure. (1967) (4)
19 Selective antagonism of endothelin-1 -induced vasoconstriction by the potassium channel opening agent, cromakalim (1991) (4)
Bradykinin Does Not Contribute to Peripheral Vascular Tone in Patients With Cirrhosis and Ascites (2006) (4)
Dual endothelin-converting enzyme/neutral endopeptidase inhibition: a novel treatment for renovascular hypertension beyond blood pressure lowering? (2011) (4)
Generation and 3-Dimensional Quantitation of Arterial Lesions in Mice Using Optical Projection Tomography (2015) (4)
Prognostic value of carotid-femoral pulse wave velocity for cardiovascular events: An IPD meta-analysis of prospective observational data from 14 studies including 16,358 subjects (2011) (3)
The endothelin system : a novel therapeutic target in cardiovascular disease (1998) (3)
Targeting Blood Vessel Stiffness to Protect Kidney Function. (2015) (3)
Screening for human immunodeficiency virus: a survey of British clinical pharmacology units. (1993) (3)
Administration of endothelin-1 in humans. (1991) (3)
The acute pressure natriuresis response is suppressed by selective ETA receptor blockade (2021) (3)
Working of the Abortion Act (1975) (3)
Renal Dysfunction Does Not Affect the Peripheral-to-Central Arterial Pressure Transfer Function (2010) (3)
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of end points in noninsulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. (2012) (3)
A transgenic strategy for analysis of the function of the endothelin-B-receptor. (2000) (3)
Advances in clinical pharmacology and therapeutics: endothelin. (1996) (3)
Endothelin antagonism reduces circulating galectin-3 in patients with proteinuric chronic kidney disease. (2018) (3)
Modulators of calcium and potassium channels: their effects on endothelin-1 binding to cardiac membranes. (1993) (3)
35 Role of endothelin-1 in the maintenance of systemic and portal haemodynamics in patients with cirrhosis: A randomised double blind placebo-controlled haemodynamic study of endothelin-A and endothelin-B receptor antagonism (2004) (3)
Treatment in the Morning versus Evening (TIME) Study: Feasibility of an OnlineStudy (2016) (3)
Regarding the accuracy of generalized transfer functions for estimating central aortic blood pressure: reply (1999) (3)
Increase in skin microcirculatory blood flow after local renin inhibition in man. (1991) (3)
Cyclophilin A is a Key mediator of Paracetamol Poisoning (2010) (2)
Blue-chip technology (1998) (2)
ABNORMAL PERIPHERAL VASCULAR-RESPONSE IN HYPERTROPHIC CARDIOMYOPATHY IN RELATION TO CLINICAL AND PROGNOSTIC FEATURES (1989) (2)
Local tissue factor pathway inhibitor release in the human forearm (2003) (2)
A new professional framework for developing future chief pharmacists (2008) (2)
Abstract 10974: Durable Reductions in Circulating Angiotensinogen and Blood Pressure Six Months After Single Doses of ALN-AGT, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Hypertensive Patients (2021) (2)
Mechanistic biomarkers provide early and sensitive detection of paracetamol-induced acute liver injury at first presentation to hospital (2013) (2)
UK supply of chlortalidone for hypertension must be restored (2013) (2)
PULSE TRANSIT TIME MEASURED FROM THE ECG AS A MARKER OF EXERCISE BLOOD PRESSURE: P1.12 (2004) (2)
Role of renin angiotensin and sympathetic nervous systems in regulation of peripheral vascular tone in patients with refractory ascites. (1998) (2)
Difference in Age-related Patterns of Arterial Stiffness and Wave Reflections among Patients with Kidney Disease: Results of the UK Research Alliance into Kidney Disease and Arterial Stiffness (UREKA) Collaboration (2010) (2)
Nitric oxide and regulation of arterial elasticity: right idea, wrong vascular bed? (2002) (2)
Correction and transparency of BNF risk charts (2009) (2)
An endothelin antagonist for resistant hypertension (2010) (2)
Endothelin Ligands and their Experimental Effects Within the Human Circulation (2001) (2)
Impaired central but stimulated humoral regulation of vascular tone in patients with cirrhosis and ascites (1996) (2)
Bradykinin has no acute effect on the response of forearm blood flow to sympathetic stimulation in man. (1990) (2)
CYCLOPHILIN A IS A MEDIATOR OF PARACETAMOL-INDUCED LIVER INJURY (2009) (2)
Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies (2021) (2)
Identification and proteomic profiling of exosomes in human cerebrospinal fluid (2012) (2)
Forearm Vessels in Man Have A Substantial Capacity for Conversion of Angiotensin I to II Which is Abolished by Enalaprilat (1987) (2)
Vascular Biology of the Endothelin System (1997) (2)
Clinical pharmacology. Blue-chip technology. (1998) (2)
Opportunities for a career in clinical pharmacology (1997) (1)
THE ROLE OF THE CLINICAL PHARMACOLOGIST IN HEALTH TECHNOLOGY APPRAISAL (HTA) (2011) (1)
Ethics of volunteer research: the role of new EC guidelines. (1991) (1)
BR 04-1MANAGEMENT OF TREATMENT-RESISTANT HYPERTENSION. (2016) (1)
Abstract 1263: Collecting Duct Endothelin B Receptors Lower Blood Pressure and Increase Sodium Excretion (2006) (1)
The Sixth International Conference on Endothelin (2000) (1)
Reply to J Rood and SR Smith (2008) (1)
Edinburgh Research Explorer Contribution of the M-3 muscarinic receptors to the vasodilator response to acetylcholine in the human forearm vascular bed (2017) (1)
Advances in clinical pharmacology and therapeutics (1996) (1)
Sildenafil (SIL) reduces serum creatinine (SCr) in patients with pulmonary arterial hypertension (PAH): Relationship to clinical outcomes (2011) (1)
Impaired endothelium-dependent vasomotion in patients with recent myocardial infarction and hyperhomocysteinemia (2003) (1)
Evaluation of urinary and plasma endothelin-like domain peptide (ELDP) in chronic kidney disease (2013) (1)
Scotland v England deal on prescribed drugs (2006) (1)
The effect of daily UVA phototherapy for 2 weeks on clinic and 24-h blood pressure in individuals with mild hypertension (2022) (1)
Scottish and Newcastle Antiemetic Pre-treatment for paracetamol poisoning study (SNAP) (2013) (1)
Altered peripheral vascular responses to vasoactive mediators in patients with pre-ascitic cirrhosis: role of nitric oxide (2001) (1)
Selective endothelin A receptor antagonism with sitaxentan reduces neointimal lesion size in a mouse model of intraluminal injury (2015) (1)
Endothelin as a Regulator of Vascular Tone in Man: Studies in Upper Limb Resistance and Capacitance Vessels (1995) (1)
Capillary Rarefaction and Impaired Microvascular Dilatation in Young Adults with a Familial Predisposition to high Blood Pressure (1996) (1)
Theeffect ofintra-arterial endothelin onresting bloodflowand sympathetically mediated vasoconstriction intheforearm ofman (1991) (1)
Treatment for Renovascular Hypertension Beyond Blood Pressure Lowering? Dual Endothelin-Converting Enzyme/Neutral Endopeptidase Inhibition : A Novel (2012) (1)
Acetylcysteine has No Mechanistic Effect in Patients at Risk of Contrast‐Induced Nephropathy: A Failure of Academic Clinical Science (2022) (1)
The clinical section of the British Pharmacological Society: prospects for the future. (2003) (1)
Author response: Endothelin signalling mediates experience-dependent myelination in the CNS (2019) (1)
Correspondence: Contribution of Nitric Oxide to Vasodilatation by Substance P in Human Forearm Vessels: Author's Reply (1997) (1)
A Cross-sectional Study of Current Doctors’ Performance in a Modified Version of a Medical School Admission Aptitude Test (2016) (1)
Response to Comment on “Cyclophilin A Is a Damage-Associated Molecular Pattern Molecule That Mediates Acetaminophen-Induced Liver Injury” (2011) (1)
Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals. (2020) (1)
Nitric oxide and the regulation of arterial elasticity: right idea, wrong vascular bed? (2002) (1)
Forearm blood flow (FBF) responses to exogenous and endogenous sympathetic stimulation in patients with cirrhosis (1998) (1)
SAFETY, PHARMACODYNAMICS, AND BLOOD PRESSURE EFFECTS OF ALN-AGT, AN RNA INTERFERENCE THERAPEUTIC TARGETING ANGIOTENSINOGEN, IN A RANDOMIZED SINGLE ASCENDING DOSE STUDY OF HYPERTENSIVE ADULTS (2021) (1)
Arterial stiffness, endothelial dysfunction and impaired fibrinolysis are pathogenic mechanisms contributing to cardiovascular risk in ANCA-associated vasculitis. (2022) (1)
Noninvasive Assessment of Atherosclerosis : from Structure to Function Series (2003) (1)
Flosequinan in heart failure (1993) (1)
Acute endothelinA receptor antagonism improves coronary artery compliance in coronary artery disease patients (1)
Contribution of angiotensin II (AII) and angiotensin receptor (AT(1)) in the pathogenesis of ascites. (1998) (1)
Renal denervation therapy for hypertension: still on trial (2019) (1)
Local nitric oxide release does not affect tachyphylaxis to angiotensin II in dorsal hand veins in man in the presence of prostaglandin synthesis inhibition. (2002) (1)
Angiotensin II Augments the Venoconstrictor Response to Deep Breath by a Pre-Synaptic Mechanism (1988) (1)
Local forearm vasoconstriction to endothelin-1 measured by venous occlusion plethysmography in vivo. (2002) (1)
Serial troponin measurements to monitor risk and response to endothelin A antagonism in chronic kidney disease (2020) (1)
Selective deletion of endothelin B receptors from vascular smooth muscle does not inhibit neointimal lesion formation (2013) (1)
Sitaxentan Reduces Serum Uric Acid In Patients With Pulmonary Arterial Hypertension: Relationship To Exercise Capacity, Clinical Worsening And Survival (2011) (1)
Clinical Potential of Combined Organic Nitrate and Phosphodiesterase Type 5 Inhibitor in Treatment-Resistant Hypertension (vol 56, pg 62, 2010) (2012) (1)
Endothelinareceptor antagonist BQ-123 provokes coronary vasodilation and blood flow increase in humans (1998) (1)
Scottish Medicines Consortium (2007) (1)
Abstract 1295: The Vasomotor Effects of Apelin in vivo in Man (2007) (0)
The roles of clinical pharmacologists in UK universities. (2012) (0)
EFFECTS OF CANDESARTAN ON LEFT VENTRICULAR AND ARTERIAL STRUCTURE AND FUNCTION IN HYPERTENSIVE PATIENTS: P3.139 (2000) (0)
We look forward to seeing progress in these and other areas in the near future. (2008) (0)
Endothelial Dysfunction in End-Stage Renal Failure is Reversed by Dialysis and L- but not D-Arginine (1996) (0)
Endothelial dysfunction. (1998) (0)
Changes in urinary ET-1 excretion in response to increased renal perfusion pressure in the rat (2013) (0)
The endothelin antagonist, TAK-044, causes vasodilatation in humans (1995) (0)
68. Potassium channel activation prevents endothelin-induced venoconstriction in vivo in humans (1991) (0)
Endothelin – Kidney Disease Blood Pressure – Independent Reduction in Proteinuria and Arterial Stiffness After Acute Endothelin-A Receptor Antagonism in Chronic Kidney Disease (2009) (0)
Neointimal lesion formation does not induce endothelin (ET) B-mediated contraction in murine femoral arteries (2013) (0)
Cyclophilin A is a novel mediator of paracetamol-induced liver injury (2009) (0)
OR-49: Increased plasma endothelin-1 and impaired vasorelaxation in mice featuring endothelial cell specific knockout of the endothelin B receptor (2003) (0)
15 MODULATION OF ENDOTHELIAL FUNCTION TO PRODUCE CARDIAC AND RENAL PROTECTION IN HYPERTENSIVE CHRONIC KIDNEY DISEASE PATIENTS (2012) (0)
Isocapnic hyperoxia impairs endogenous fibrinolysis in healthy men: A-196 (2005) (0)
Explorer Direct comparison of selective endothelin A and non-selective endothelin A / B receptor blockade in chronic heart failure (2017) (0)
cells proliferation of bovine adrenocortical ANG II AT1 and AT2 receptors both inhibit (2008) (0)
Localization and function of ET-1 and ET receptors in small arteries post-myocardial infarction (2016) (0)
Does ACE genotype influence the development of left ventricular hypertrophy in untreated hypertension (1996) (0)
Cyclophilin A is a damage-associated molecular pattern that mediates paracetamol-induced liver injury (2011) (0)
Edinburgh Research Explorer Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease (2021) (0)
Bradykinin does not Attenuate Sympathetic Vasoconstriction in Forearm Resistance vessels in Man (1989) (0)
A call to incorporate systems theory and human factors into the existing investigation of harm in clinical research involving healthcare products. (2017) (0)
442P PLATELET-DERIVED NITRIC OXIDE IN HYPERTENSIVE AND NORMOTENSIVE CONTROL SUBJECTS (2007) (0)
Endogenous Bradykinin does not Contribute to the Maintenance of Basal Peripheral Arteriolar Tone in Man (2000) (0)
URINARY EXOSOMES ARE A SOURCE FOR BIOMARKER DISCOVERY IN ACUTE KIDNEY INJURY (2009) (0)
Pathological role of extracellular vesicle cell-to-cell signalling in nephrotoxic renal injury (2015) (0)
Arterial stiffness in healthy children and children with diabetes (2007) (0)
No adverse haemodynamic interaction between sildenafil and alcohol in healthy volunteers (2003) (0)
QT prolongation in poisoning: Sources of measurement error and effects of treatment (2014) (0)
Novel therapeutic approaches to chronic kidney disease. (2013) (0)
The pressure natriuresis response is not affected by SGLT2 inhibition in rats with Type 1 diabetes mellitus (2018) (0)
Increased vascular responses to endothelin-1 in essential hypertension (1993) (0)
With the Angiotensin II Antagonist Losartan Trial Hoc Analysis of the Reduction of End Points in Noninsulin-Dependent Diabetes Mellitus Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment: A Post (2012) (0)
Circulating argonaute-bound microRNA-126 reports vascular dysfunction & response to treatment in acute & chronic kidney disease (2020) (0)
Synthesis of Carbohydrate Esters as Green Antibacterial/antifungal Agents (2015) (0)
Atrial Natriuretic Peptide is a Weak Arteriolar Dilator in the Human Forearm with No Effect on Dorsal Hand Veins (1987) (0)
A changing scientific and pharmaceutical landscape: The challenge for pharmacology (2018) (0)
011. CHORIORETINAL THICKNESS TRACKS DISEASE ACTIVITY IN CLINICAL ANCA VASCULITIS (2019) (0)
THE EFFECT OF ERT AND HRT ON FOREARM BLOOD FLOW AND ENDOTHELIAL FUNCTION IN POSTMENOPAUSAL WOMEN (1997) (0)
PP.23.428 DIETARY INTAKE AND ARTERIAL STIFFNESS; A CROSS-SECTIONAL STUDY OF PATIENTS ATTENDING AN OUTPATIENT HYPERTENSION CLINIC (2019) (0)
MEASUREMENT OF FOREARM BLOOD FLOW. AUTHORS' REPLY (1996) (0)
3.5 The contribution of parental blood pressures to the relationship between low birthweight and adult high blood pressure (1997) (0)
Endothelin-1 Antagonises Beta-Adrenergic Stimulation in Human Right Atrial Myocardium (2003) (0)
Explorer Identification and proteomic profiling of exosomes in human cerebrospinal fluid (2017) (0)
Endothelin-A receptor antagonism offers patients with chronic kidney disease cardiovascular and renal protection (2008) (0)
Urotensin receptor (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (0)
Endothelin-A receptor antagonism offers hypertensive patients with chronic kidney disease cardiovascular and renal protection (2008) (0)
Deprivation-based cardiovascular risk scores may lead to postcode prescribing (2008) (0)
Hypertension Highlights Arterial Stiffness and Hypertension Emerging Concepts (2009) (0)
85 Venoconstriction to endothelin-1, but not noradrenaline, is increased in patients with chronic renal failure (1993) (0)
Coronary Artery Disease Sildenafil Citrate Potentiates the Hypotensive Effects of Nitric Oxide Donor Drugs in Male Patients With Stable Angina (2016) (0)
BR 04-1MANAGEMENT OF TREATMENT-RESISTANT HYPERTENSION. (2016) (0)
Endothelins and their antagonists in chronic kidney disease (2018) (0)
Therapeutic targetting of endothelin and nitric oxide in hypertension and chronic kidney disease (2013) (0)
health economic assessments Prognosis without treatment as a modifier in (2007) (0)
Is there a need for novel antihypertensive therapies (2004) (0)
WHAT IS THE BEST WAY TO MEASURE PROTEINURIA IN CLINICAL TRIALS OF ANTIPROTEINURIC DRUGS (2011) (0)
Faculty Opinions recommendation of Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. (2008) (0)
OPEN The eye, the kidney, and cardiovascular disease: old concepts, better tools, and new horizons (2020) (0)
Low dose thiazide diuretic Is not available for prescribing (1994) (0)
Effect of High Altitude, Cold Exposure and Exercise on Plasma Endothelin-1 and Markers of Endothelial Function in Man (1998) (0)
OP-TOXS170146 380..391 (2017) (0)
Localization of the Endothelin-B Receptor Using a Transgenic Approach (2004) (0)
Edinburgh Explorer Generation and 3-Dimensional Quantitation of Arterial Lesions in Mice Using Optical Projection Tomography (2018) (0)
SMJ May 2007 vs6.qxp (2007) (0)
Marked Rise of Renin Associated with Renin Inhibition in Man (1985) (0)
28 A physiological role for endothelin in maintenance of yascular tone in man (1994) (0)
University of Dundee Prevention And Treatment of Hypertension With Algorithm-based therapy ( PATHWAY ) number 2 (2015) (0)
The role of molecular biology in pharmacodynamic research (2001) (0)
The Sixth International Conference on Endothelin. October 1999, Montreal, Canada. (2000) (0)
Clinical utility of retinal and choroidal OCT in the assessment of chronic kidney disease (2015) (0)
Acute SGLT2 Inhibition and the Pressure Natriuresis Response in Rats with Type 1 Diabetes (2019) (0)
Tissue Specific Knockout of the Mouse Endothelin B receptor (2002) (0)
LocalL-NG-monomethyl-arginine attenuates thevasodilator action ofbradykinin inthehumanforearm (1994) (0)
Effect of sitaxentan on plasma biomarkers of proendothelin-1 synthesis in patients with chronic kidney disease (2013) (0)
Urinary microparticles are a source of protein for biomarker discovery in sepsis (2008) (0)
Endothelin levels in cardiac arrest (1992) (0)
THE EFFECT OF ROSUVASTATIN ON ENDOTHELIAL FUNCTION IN PATIENTS WITH MODERATE HYPERCHOLESTEROLAEMIA: P1.111 (2004) (0)
THE ENDOTHELIAL CELL ENDOTHELIN B RECEPTOR PLAYS AN IMPORTANT ROLE IN THE CLEARANCE OF ET-1: P1.105 (2004) (0)
Targeting Blood Vessel Stiffness to Protect Kidney (2015) (0)
The effect of rosuvastatin on endothelial function in patients with moderate hypercholesterolaemia (2004) (0)
The role of endothelin-1 in the regulation of blood pressure in early diabetes mellitus (2015) (0)
Prospects for novel therapeutic approaches to hypertension (2018) (0)
The scottish model: Scottish medicines consortium (SMC) (2013) (0)
Abnormalities of microvascular structure and related vascular function in subjects with familial predisposition to hypertension (1995) (0)
Hyporesponsiveness to endothelin-1 in patients with well compensated cirrhosis is mediated through ETB receptors. (1999) (0)
CHRONIC ENDOTHELIN-A RECEPTOR ANTAGONISM REDUCES PROTEINURIA, BLOOD PRESSURE & ARTERIAL STIFFNESS IN CHRONIC KIDNEY DISEASE (2009) (0)
Angiotensin II does not contribute to basal forearm vascular tone in healthy man (1996) (0)
729-3 Left Ventricular Hypertrophy in Essential Hypertension Depends on ACE Genotype (1995) (0)
A Comparison of the Haemodynamic Effects Pentaerythritol Tetranitrate and Isosorbide Mononitrate in Healthy Men (2003) (0)
PERIPHERAL VASCULAR-RESPONSES IN HYPERTROPHIC CARDIOMYOPATHY - CLINICAL AND PROGNOSTIC-SIGNIFICANCE (1990) (0)
62 CHRONIC ENDOTHELIN-A RECEPTOR ANTAGONISM MODIFIES NOVEL CARDIOVASCULAR RISK FACTORS IN CKD (2012) (0)
Urotensin receptor in GtoPdb v.2021.3 (2021) (0)
Vasopressin regulates uptake of exosomes by kidney collecting duct cells (2014) (0)
Pressure volume relations in the mouse using contrast enhanced echocardiography (2004) (0)
Educating nurses to prescribe – don’t forget about medical students (2017) (0)
Life as an academic clinical pharmacologist. (1996) (0)
Oxidised Ldl Induces Increased Expression of Angiopoietin-2 in Human Endothelial Cells (2002) (0)
Monitoring ambulatory blood pressure in general practice. (1992) (0)
Proteomic investigation of human urinary microparticles (2009) (0)
1 Vasopressin regulates extracellular vesicle uptake by kidney collecting duct cells (2016) (0)
Are the Scots getting a better deal on prescribed drugs than the English (2018) (0)
CONSUMPTION OF HIGH POLYPHENOL GRAPE SEED FAILED TO LOWER AMBULATORY BLOOD PRESSURE: PP.23.427 (2010) (0)
Endothelin System in Chronic Kidney Disease (2008) (0)
Thepotassium channel opening drugcromakalim produces arterioselective vasodilation intheupperlimbs ofhealthy volunteers (1989) (0)
Haemodynamic effects of chronic administration of losartan, an angiotensin II receptor anatagonist, in patients with cirrhosis and portal hypertension (2002) (0)
OVER-REGULATION OF RESEARCH: THE UK PRESCRIPTION (2011) (0)
Radial-finger pulse wave velocity increases in response to glyceryl trinitrate (2009) (0)
Phase I Trials on Anti-hypertensive Drugs (2020) (0)
MODULATION OF ENDOTHELIAL FUNCTION TO PRODUCE CARDIO-AND RENO-PROTECTION IN HYPERTENSIVE CHRONIC KIDNEY DISEASE PATIENTS (2012) (0)
A receptor selective antagonist BMS-193884 in healthy men (2005) (0)
15 Effect of guidelines on the management of hypertension in general practice: An audit of revised guidelines in Lothian (1994) (0)
The Effect of Proadrenomedullin N-Terminal 20 Peptide (PAMP) in the Human Forearm Vascular Bed (1999) (0)
Antagonists in Treatment-Resistant Hypertension DORADO: Opportunity Postponed : Lessons From Studies of Endothelin Receptor (2012) (0)
Clinical Utility Of Optical Coherence Tomography (Oct) In High Cardiovascular Risk Patients (2015) (0)
Flosequinan in heart failure. (1993) (0)
Update on Hypertension Management 2018 , 19 , nr . 67 ENDOTHELIAL FACTORS IN THE PATHOGENESIS AND TREATMENT OF CHRONIC KIDNEY DISEASE (2018) (0)
A Call to Incorporate Systems-Theoretic Advances and Human Factors into Our Existing Investigations of Harm in Human Clinical Research Involving Healthcare Products (2017) (0)
HUMAN CEREBROSPINAL FLUID CONTAINS EXOSOMES THAT REPRESENT A NOVEL RESERVOIR FOR THERAPEUTIC BIOMARKER DISCOVERY (2009) (0)
Explorer Impaired Pressure Natriuresis and Non-Dipping Blood Pressure in Rats with Early Type 1 Diabetes Mellitus (2018) (0)
Proportion of patients with previously uncontrolled hypertension who achieve target blood pressure through participation in the BHS's prevention and treatment of hypertension with algorithm based therapy (PATHWAY) trials (2012) (0)
Methods used to determine the prevalence and causes of prescribing errors amongst junior doctors in Scotland (2011) (0)
Greater Cardiac Hypertrophy in Hypertensive Rats (2016) (0)
Edinburgh Research Explorer Mechanisms for an effect of acetylcysteine on renal function after exposure to radio-graphic contrast material (2012) (0)
Chapter 26 - The Endothelins (1997) (0)
Endothelial Biomedicine: The Endothelium at High Altitude (2007) (0)
Lessons from a patient with Turner syndrome. (2013) (0)
Scottish Society of Physicians – 52nd Annual Meeting (2011) (0)
Circulating miRNAs as potential biomarker for acute endothelial toxicity (2015) (0)
ENDOTHELIAL CELL-SPECIFIC KNOCKOUT OF THE ENDOTHELIN B RECEPTOR RESULTS IN HYPERTENSION THAT IS RESISTANT TO SALT: 1D.3 (2004) (0)
Observing the NICEties of hypertension management. (2012) (0)
Diurnal variation in blood pressure and arterial stiffness in CKD – the role of endothelin-1 (2014) (0)
Post-registration and seamless education: the need for global reform (2007) (0)
Investigation of the endocrine and haemodynamic changes in resistant hypertension, and its response to spironolactone or amiloride: the PATHWAY-2 mechanisms study (2018) (0)
Letter by Payne and Webb regarding article, "agreement among cardiovascular disease risk calculators". (2013) (0)
Treatment-resistant hypertension: The challenges for drug treatment (2013) (0)
A call to incorporate systems theory and human factors into the existing investigation of harm in clinicalresearch involving healthcare products (2017) (0)
Health technology Assessment: The role of the clinical pharmacologist (2018) (0)
Circulating microRNA profiles in human drug-induced liver injury (2014) (0)
function in humans Physiological role of nitric oxide in regulation of renal (2013) (0)
Impaired pressure natriuresis and urinary ET-1 excretion in a rat model of Type I diabetes mellitus (2014) (0)
Intra-arterial substance P is a potent stimulant for the release of tissue plasminogen activator in the human forearm via a flow independent mechanism (1996) (0)
Acetaminophen Adverse effects Hypertension Cardiovascular diseases Asthma Kidney disease Gastrointestinal Bleeding Pregnancy Word Count : 6086 Tables : 0 Figures : 1 Conflict of Interest Statement (2018) (0)
CLINICAL STUDIES Coronary Artery Disease Sildenafil Citrate Potentiates the Hypotensive Effects of Nitric Oxide Donor Drugs in Male Patients With Stable Angina (2000) (0)
83. Effect of intra-arterial substance P on the release of tissue plasminogen activator in the human forearm (1996) (0)
Isocapnic hyperoxia and hypoxia do not affect endothelium-dependent vasodilatation in healthy males: A-212 (2004) (0)
90 Enhanced venoconstriction to endothelin-1 in essential hypertension (1993) (0)
[PS 08-38] CLINICAL UTILITY OF OPTICAL COHERENCE TOMOGRAPHY (OCT) IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD) (2016) (0)
Author's response to reviews Title: Augmentation index assessed by applanation tonometry is elevated in Marfan Syndrome Authors: (2007) (0)
Scientific Business Abstracts of the 112th Annual Meeting of the Association of Physicians of Great Britain and Ireland. (2018) (0)
Consultant appraisal: serving two masters. (2001) (0)
Scientific Business Abstracts of the 112th Annual Meeting of the Association of Physicians of Great Britain and Ireland. (2018) (0)
On the Limits of Dr. Black's Powers (2000) (0)
02.04 DETERMINANTS OF ARTERIAL STIFFNESS IN PATIENTS WITH CORONARY ARTERY DISEASE (2006) (0)
This article is based on a lecture given to the British Pharmacological Society at their December 1995 meeting in Brighton following the award to Professor David Webb in 1994 of the SmithKline Beecham Prize for Research (1997) (0)
Possibility in the Actual World (2003) (0)
Amplifying the impact of clinical pharmacology and therapeutics (2020) (0)
British Pharmacological Society: supporting safer prescribing (2017) (0)
Small Interfering RNA Therapeutics in Hypertension: A Viewpoint on Vasopressor and Vasopressor‐Sparing Strategies for Counteracting Blood Pressure Lowering by Angiotensinogen–Targeting Small Interfering RNA (2022) (0)
The Biological Activity of Novel S-Nitrosothiols as Slow Release Nitric Oxide Donor Drugs: Therapeutic Potential in Vascular Disease (1998) (0)
Budget impact analysis of a pilot polypharmacy clinic (2022) (0)
S-28-1: CARDIOVASCULAR OUTCOMES IN ADULTS WITH HYPERTENSION WITH EVENING VERSUS MORNING DOSING OF USUAL ANTIHYPERTENSIVES IN THE UK. THE TIME STUDY (2023) (0)
Anatomically unbiased analysis of renal BOLD magnetic resonance images reveals disruption of corticomedullary gradient during chronic angiotensin II infusion (2013) (0)
Endothelin blockade prevents the long-term cardiovascular and renal sequelae of acute kidney injury in mice (2022) (0)
Endothelial Function Potentiation of Bradykinin-Induced Tissue Plasminogen Activator Release by Angiotensin-Converting Enzyme Inhibition (2016) (0)
Uk Translational Medicine and Therapeutics (Tmat) Phd Training (2015) (0)
ADMINISTRATION OF ENDOTHELIN-1 IN HUMAN. AUTHOR'S REPLY (1991) (0)

This paper list is powered by the following services:

Other Resources About David Webb

What Schools Are Affiliated With David Webb ?

David Webb is affiliated with the following schools:

David Webb 's Academic­Influence.com Rankings